AFT Pharmaceuticals Limited
Research AFT Pharmaceuticals Limited (AFP.AX) on Bullrun: market cap AUD 377.55M, P/E 30.0, dividend yield 0.4%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerAFP.AX
- ExchangeAU
- CountryNew Zealand
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyAUD
- Market capAUD 377.55M
- P/E30.0
- Dividend yield0.4%
- Financial periodFY2026
- RevenueNZD 251.19M
- Revenue growth22.2%
- Net incomeNZD 14.73M
- Free cash flow-NZD 19.30M
- Gross margin42.6%
Valuation Snapshot
latest market cap is AUD 377.55M; P/E is 30.0; dividend yield is 0.4%.
Peer valuation comparison
Latest P/E is 30x versus a Healthcare sector median of 24.73x (21.3% above).
Latest dividend yield is 0.38% versus a Healthcare sector median of 1.81% (79.0% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2026 | NZD 251.19M | NZD 14.73M | -NZD 19.30M | 42.6% | n/a | NZD 10.24M | NZD 54.11M | NZD 110.28M |
| FY2025 | NZD 205.49M | NZD 11.96M | NZD 6.23M | 43.4% | 0.11 | NZD 11.11M | NZD 30.00M | NZD 97.64M |
| FY2024 | NZD 194.03M | NZD 15.61M | NZD 19.33M | 44.8% | 0.15 | NZD 12.04M | NZD 32.19M | NZD 87.80M |
| FY2023 | NZD 155.82M | NZD 10.65M | NZD 2.45M | 46.3% | 0.1 | NZD 4.75M | NZD 38.05M | NZD 73.27M |
| FY2022 | n/a | n/a | n/a | n/a | 0.19 | n/a | n/a | n/a |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-16 | AUD 377.55M | 30.0 | 0.4% | 0.01 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0.01 AUD, yield 0.4%.
| Year | Dividends/share |
|---|---|
| FY2026 | 0.01 NZD |
| FY2025 | 0.01 NZD |
| FY2024 | 0.01 NZD |
| FY2023 | 0.01 NZD |
About AFT Pharmaceuticals Limited
AFT Pharmaceuticals Limited, together with its subsidiaries, develops, markets, and distributes pharmaceutical products in New Zealand, Australia, Asia, and internationally. The company offers proprietary and in-licensed products, including patented, branded, and generic drugs; and products for use in the areas of allergy, cold and flu, digestive health, eye care, first aid, natural health, pain management, skin care, sleeping aids, supplements, and other products.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is AFT Pharmaceuticals Limited's market cap?
AFT Pharmaceuticals Limited's market capitalization is AUD 377.55M.
What is AFT Pharmaceuticals Limited's P/E ratio?
AFT Pharmaceuticals Limited's price-to-earnings (P/E) ratio is 30.0.
Does AFT Pharmaceuticals Limited pay a dividend?
AFT Pharmaceuticals Limited has a dividend yield of 0.4%.
What does AFT Pharmaceuticals Limited do?
AFT Pharmaceuticals Limited, together with its subsidiaries, develops, markets, and distributes pharmaceutical products in New Zealand, Australia, Asia, and internationally. The company offers proprietary and in-licensed products, including patented, branded, and generic drugs; and products for use in the areas of allergy, cold and flu, digestive health, eye care, first aid, natural health, pain management, skin care, sleeping aids, supplements, and other products. It has a research and development collaboration with Hyloris Pharmaceuticals SA for the development of the Maxigesic IV product.